25 citations
,
September 2010 in “Journal of Cutaneous Medicine and Surgery” The study found that Central Centrifugal Cicatricial Alopecia mainly affects middle-aged African descent women, is linked to certain hair care practices and genetics, and often goes undiagnosed for years.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
May 2023 in “Archives of dermatological research” Some factors like thyroid disease, diabetes treatment, hair dryers, natural hairstyles, and scalp conditions can affect the treatment results for a hair loss condition called CCCA.
April 2017 in “Journal of Investigative Dermatology” Applying pseudoceramide improved skin and hair health.
1 citations
,
January 1979 in “International Journal of Dermatology” Cyproterone acetate effectively treats hirsutism and related conditions.
7 citations
,
September 2014 in “Beni-Suef University Journal of Basic and Applied Sciences” Cuscuta reflexa extracts and an isolate promoted hair growth and could be natural treatments for hair loss.
7 citations
,
January 2017 in “Annals of Dermatology” Oral cyclosporine combined with Pantogar® effectively treats twenty-nail dystrophy.
May 2015 in “Journal of The American Academy of Dermatology” Combination therapy with cyclosporine and low-dose corticosteroid shows favorable long-term results for treating alopecia areata.
VCFO effectively treats fungal infections in cats and promotes hair regrowth.
10 citations
,
April 1964 in “Journal of the American Geriatrics Society” Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.
22 citations
,
July 1987 in “Transplantation” Topical cyclosporine significantly extends skin graft survival in rats.
September 2024 in “Journal of Parasite Science” Dermatophytosis in cats was most common in young, male Persian cats, with symptoms like hair loss and crusts.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
15 citations
,
November 1998 in “Australasian Journal of Dermatology” Cicatricial pemphigoid rarely affects the scalp but is hard to treat when it does.
April 2020 in “Journal of the Endocrine Society” Block and replace therapy improved symptoms in recurrent cyclic Cushing’s disease.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
13 citations
,
January 2013 in “Applied and Environmental Microbiology” A gene in Sebekia benihana, CYP-sb21, is needed for a specific reaction on the drug Cyclosporine A, which could be important for hair growth without affecting the immune system.
April 2019 in “Journal of parasitic diseases” A Persian cat and its owner fully recovered from Cheyletiellosis after treatment.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
32 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” 17-β-Estradiol applied to the skin stops hair growth, while ICI 182 780 helps hair grow in mice.
1 citations
,
July 2012 in “Springer eBooks” The document concludes that more research is needed to better understand and treat scarring hair loss conditions.
125 citations
,
May 2019 in “Phytomedicine” Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.